Rigvir (ECHO-7 Virus)
Oncology (historically melanoma)
Approved/Commercial (in Latvia)Active
Key Facts
Indication
Oncology (historically melanoma)
Phase
Approved/Commercial (in Latvia)
Status
Active
Company
About Rigvir
Rigvir Group is a private biotech company based in Riga, Latvia, developing oncolytic virotherapy based on its proprietary ECHO-7 virus (Rigvir). The company's primary strategy involves licensing its technology for commercial production and therapeutic use, while also exploring non-medical applications like cancer prevention supplements. While Rigvir was registered as a medicine in Latvia in 2004, the company's current commercial focus appears to be on industrial/scientific sales and regional licensing deals rather than broad pharmaceutical commercialization.
View full company profile